Latest Conference Articles

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.

These data may upend the typically underperforming CETP inhibitor field with an accessible, oral medication for lowering LDL cholesterol.

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

This summary features a variety of abstracts to be presented at the RAD meeting in June 2025, highlighting new data in atopic dermatitis and the dermatology space in general.

This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.

During her ATS interview, Lisa Wood, PhD, spoke about economic and geographic disparities and their connection to diet and related respiratory health outcomes.

This ATS interview features Lisa Wood, PhD, discussing recent findings related to childhood dietary intake and its connection to respiratory health.

Bose explains her research on vaping among millennial adults who may be at peak lung health, describing the diverse landscape of vaping devices and products.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Prevot describes her research exploring the relationship between OSA severity and abdominal obesity metrics as well as changes in both metrics following CPAP.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.